

Resource Summary Report

Generated by [NIF](#) on Jul 31, 2026

Brilliant Violet 650™ anti-mouse TNF-?

RRID:AB_2562450

Type: Antibody

Proper Citation

BioLegend Cat# 506333, RRID:AB_2562450

Antibody Information

URL: http://antibodyregistry.org/AB_2562450

Proper Citation: BioLegend Cat# 506333, RRID:AB_2562450

Target Antigen: TNF-alpha

Host Organism: rat

Clonality: monoclonal

Comments: Applications: ICFC

Antibody Name: Brilliant Violet 650™ anti-mouse TNF-?

Description: This monoclonal targets TNF-alpha

Target Organism: mouse

Clone ID: Clone MP6-XT22

Antibody ID: AB_2562450

Vendor: BioLegend

Catalog Number: 506333

Record Creation Time: 20250819T234625+0000

Record Last Update: 20250820T062248+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 650™ anti-mouse TNF-?.

No alerts have been found for Brilliant Violet 650™ anti-mouse TNF-?.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Xie M, et al. (2025) Tumor-resident probiotic *Clostridium butyricum* improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression. Cancer cell.

Sharma P, et al. (2025) Smoking-induced gut microbial dysbiosis mediates cancer progression through modulation of anti-tumor immune response. iScience, 28(3), 112002.

Braun LM, et al. (2025) Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. Cancer cell, 43(2), 269.

Wang L, et al. (2024) Targeting the HSP47-collagen axis inhibits brain metastasis by reversing M2 microglial polarization and restoring anti-tumor immunity. Cell reports. Medicine, 5(5), 101533.

Cohen GS, et al. (2023) Transplantation elicits a clonally diverse CD8+ T cell response that is comprised of potent CD43+ effectors. Cell reports, 42(8), 112993.

Ramirez-Valdez RA, et al. (2023) Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression. Cell reports, 42(6), 112599.

Lin YH, et al. (2023) Small intestine and colon tissue-resident memory CD8+ T cells exhibit molecular heterogeneity and differential dependence on Eomes. Immunity, 56(1), 207.

Arieta CM, et al. (2023) The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection. Cell, 186(11), 2392.

Baharom F, et al. (2022) Systemic vaccination induces CD8+ T cells and remodels the tumor microenvironment. Cell, 185(23), 4317.

Rosenbaum SR, et al. (2020) FOXD3 Regulates VISTA Expression in Melanoma. Cell reports, 30(2), 510.

Kumar R, et al. (2020) Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral Leishmaniasis. Cell reports, 30(8), 2512.